References
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. doi:https://doi.org/10.1056/NEJMoa2001017.
- Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46. doi:https://doi.org/10.1007/s10096-004-1271-9.
- Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–09. doi:https://doi.org/10.1001/jama.289.21.JOC30885.
- Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, Hoschler K, Brown K, Galiano M, Myers R, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill. 2012;17:20290.
- Vogel OA, Manicassamy B. Broadly protective strategies against influenza viruses: universal vaccines and therapeutics. Front Microbiol. 2020;11:135. doi:https://doi.org/10.3389/fmicb.2020.00135.
- Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–609. doi:https://doi.org/10.7326/0003-4819-145-8-200610170-00139.
- Guarner J, Hale GL. Four human diseases with significant public health impact caused by mosquito-borne flaviviruses: west Nile, Zika, dengue and yellow fever. Semin Diagn Pathol. 2019;36:170–76. doi:https://doi.org/10.1053/j.semdp.2019.04.009.
- Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A. Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention. Infect Dis Clin North Am. 2019;33:1003–25. doi:https://doi.org/10.1016/j.idc.2019.08.006.
- Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019;17:593–606. doi:https://doi.org/10.1038/s41579-019-0233-2.
- World Health Organization. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do. [cited 2020 May 7]. https://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf
- Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi:https://doi.org/10.1136/bmj.m1256.
- World Health Organization. [cited 2020 May 7]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- Wang C, Liu Z, Chen Z, Huang X, Xu M, He T, Zhang Z. The establishment of reference sequence for SARS‐CoV‐2 and variation analysis. J Med Virol. 2020. doi:https://doi.org/10.1002/jmv.25762.
- Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784–90. doi:https://doi.org/10.1016/j.csbj.2020.03.025.
- Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet. 2020;20(4):398–400. doi:https://doi.org/10.1016/S1473-3099(20)30141-9.
- Forthal DN. Functions of antibodies. Microbiol Spectr. 2014;2:1–17.
- Liu JP, Manheimer E, Shi Y. Systematic review and meta-analysis on the integrative traditional Chinese and Western medicine in treating SARS. Chin J Integr Med. 2005;25:1082–88.
- Jenkins MJ, Campos SM, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. doi:https://doi.org/10.1093/infdis/jiu396.
- Manzoli L, Vito CD, Salanti G, D’Addario M, Villari P, Ioannidis JPA. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PlosOne. 2011;6(9):e24384. doi:https://doi.org/10.1371/journal.pone.0024384.
- Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020;21(7):2272. doi:https://doi.org/10.3390/ijms21072272.
- Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, O’Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886–91. doi:https://doi.org/10.1164/rccm.200702-271OC.
- Seltsam A. Pathogen inactivation of cellular blood products - an additional safety layer in transfusion medicine. Front Med (Lausanne). 2017;4:219. doi:https://doi.org/10.3389/fmed.2017.00219.
- Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. [cited 2020 May 7]. https://apps.who.int/iris/bitstream/handle/10665/135591/WHO_HIS_SDS_2014.8_eng.pdf?sequence=1
- Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, Baker S, Nicol S, Conton B, Johnson W, et al. Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. J Infect. 2017;74(3):302–09. doi:https://doi.org/10.1016/j.jinf.2016.11.009.
- Medscape: Drugs & Diseases Whole Blood (Blood component). [cited 2020 May 7]. https://reference.medscape.com/drug/whole-blood-999509#4
- Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020. doi:https://doi.org/10.1001/jama.2020.4783.
- Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386–89. doi:https://doi.org/10.1080/22221751.2020.1729071.
- Katz J, Parikh K. Intravenous Immunoglobulin. Medscape: drugs & diseases clinical procedures. [cited 2020 May 7]. https://emedicine.medscape.com/article/210367-overview
- Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29:491–98. doi:https://doi.org/10.1093/intimm/dxx039.
- Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188(1):5–12. doi:https://doi.org/10.1086/376870.
- Shopsin B, Kaveri SV, Bayry J. Tackling difficult Staphylococcus aureus infections: antibodies show the way. Cell Host Microbe. 2016;20:555–57. doi:https://doi.org/10.1016/j.chom.2016.10.018.
- Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1–11. doi:https://doi.org/10.1111/j.1365-2249.2005.02834.x.
- Samson M, Fraser W, Lebowitz D. Treatments for primary immune thrombocytopenia: a review. Cureus. 2019;11:e5849. doi:https://doi.org/10.7759/cureus.5849.
- Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, et al. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med. 2016;8(357):357ra124. doi:https://doi.org/10.1126/scitranslmed.aag1153.
- Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci. 2004;25(6):306–10. doi:https://doi.org/10.1016/j.tips.2004.04.002.
- Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011;164:2–5. doi:https://doi.org/10.1111/j.1365-2249.2011.04387.x.
- Immunoglobulin therapy and other medical therapies for antibody deficiencies. [cited 2020 May 7]. https://primaryimmune.org/treatment-information/immunoglobulin-therapy
- Cao W, Liu X, Bai T, Fan H, Hong K, Song H, Han Y, Lin L, Ruan L, Li T. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease. Open Forum Infect Dis. 2020;7(3):ofaa102. doi:https://doi.org/10.1093/ofid/ofaa102.
- Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virusdisease. 2020;31(1):13–21. doi:https://doi.org/10.1007/s13337-020-00571-5.
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80. doi:https://doi.org/10.1016/j.cell.2020.02.052.
- Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41(5):355–59. doi:https://doi.org/10.1016/j.it.2020.03.007.
- Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi:https://doi.org/10.1038/s41467-020-16256-y.
- Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613-620. doi:https://doi.org/10.1038/s41423-020-0400-4.
- Terpstra FG, Parkkinen J, Tolo H, Koenderman AH, Ter Hart HG, von Bonsdorff L, Torma E, van Engelenburg FA. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang. 2006;90:21–32. doi:https://doi.org/10.1111/j.1423-0410.2005.00710.x.
- Caballero S, Nieto S, Gajardo R, Jorquera JI. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nano filtered intravenous immunoglobulin. Biologicals. 2010;38(4):486–93. doi:https://doi.org/10.1016/j.biologicals.2010.02.008.
- Poelsler G, Berting A, Kindermann J, Spruth M, Hammerle T, Teschner W, Schwarz HP, Kreil TR. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang. 2008;94(3):184–92. doi:https://doi.org/10.1111/j.1423-0410.2007.01016.x.
- Roberts PL, Dunkerley C, Walker C. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation. Biologicals. 2012;40(5):345–52. doi:https://doi.org/10.1016/j.biologicals.2012.04.007.
- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. doi:https://doi.org/10.1016/S0140-6736(20)30251-8.
- Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986–93. doi:https://doi.org/10.1038/cr.2013.92.
- Qiu Y, BoZhao Y, Wang Q, YanLi J, JianZhou Z, Ce-Heng L, YiGe X. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. Microbes Infect. 2020. doi:https://doi.org/10.1016/j.micinf.2020.03.003.
- Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel corona virus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457–60. doi:https://doi.org/10.1007/s11427-020-1637-5.
- He J, Tao H, Yan Y, Huang SY, Xiao Y. Molecular mechanism of evolution and human infection with SARS-CoV-2. Viruses. 2020;12:428. doi:https://doi.org/10.3390/v12040428.
- Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy. 2020. doi:https://doi.org/10.1111/all.14345.
- Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129–33. doi:https://doi.org/10.1016/j.ijid.2016.06.015.
- Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China. Eur Respir J. 2020;2000547. doi:https://doi.org/10.1183/13993003.00547-2020.
- Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019;56(3):308–21. doi:https://doi.org/10.1007/s12016-017-8648-x.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. doi:https://doi.org/10.1056/NEJMoa2002032.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–69. doi:https://doi.org/10.1001/jama.2020.1585.
- Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. Am J Roentgenol. 2020;214:1–7. doi:https://doi.org/10.2214/AJR.20.22954.
- Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi:https://doi.org/10.1186/1743-422X-2-69.
- Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020. doi:https://doi.org/10.1016/S2213-2600(20)30172-7.
- Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202–05. doi:https://doi.org/10.1172/JCI137647.
- Clark DR, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–75. doi:https://doi.org/10.1016/S0140-6736(20)30317-2.
- Yeh K, Chiueh T, Siu L. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–22. doi:https://doi.org/10.1093/jac/dki346.
- Zhao J, Perera RAPM, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Vir. 2015;89(11):6117–20. doi:https://doi.org/10.1128/JVI.00446-15.
- U.S. FDA. Recommendations for investigational COVID-19 convalescent plasma. [cited 2020 May 7]. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
- Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52(1):65S–79S. doi:https://doi.org/10.1111/j.1537-2995.2012.03663.x.
- Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015–19. doi:https://doi.org/10.1128/JVI.02015-19.
- Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020. doi:https://doi.org/10.1001/jama.2020.4940.
- Crowe JE, Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol. 2001;167(7):3910–18. doi:https://doi.org/10.4049/jimmunol.167.7.3910.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients withCOVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi:https://doi.org/10.1016/S0140-6736(20)30566-3.
- Xu D, Zhang Z, Jin L, Chu F, Mao Y, Wand H, Liu M, Wang M, Zhang L, Gao GF, et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur J Clin Microbiol Infect Dis. 2005;24(3):165–71. doi:https://doi.org/10.1007/s10096-005-1299-5.
- Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, Tian Y, Sin NN. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;16(10):1698–707. doi:https://doi.org/10.7150/ijbs.45357.
- Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa344.
- Liu L, Xie J, Sun J, Han Y, Zhang C, Fan H, Liu Z, Qiu Z, He Y, Li T. Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients. Scand J Infect Dis. 2011;43(6–7):515–21. doi:https://doi.org/10.3109/00365548.2011.560184.
- WHO. International clinical trials registry platform (ICTRP). [cited 2020 May 7]. https://www.who.int/ictrp/en/
- U.S. FDA. Recommendations for investigational COVID-19 convalescent plasma. [cited 2020 May 7]. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/investigational-new-drug-ind-or-device-exemption-ide-process-cber
- Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus. 2015;4:709. doi:https://doi.org/10.1186/s40064-015-1490-9.
- Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, Wang Y, Cui H, Pan K, Xu A. Diagnostic value and dynamic variance of serum antibody in corona virus disease 2019. Int J Infect Dis. 2020;94:49–52. doi:https://doi.org/10.1016/j.ijid.2020.03.065.
- Vashist SK. Invitro diagnostic assays for Covid-19: recent advances and emerging trends. Diagnostics. 2020;10(4):202. doi:https://doi.org/10.3390/diagnostics10040202.
- Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, et al. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J Vir Methods. 2005;128:21–28. doi:https://doi.org/10.1016/j.jviromet.2005.03.021.
- Wu HS, Chiu SC, Tseng TC, Lin SF, Lin JH, Hsu YF, Wang MC, Lin TL, Yang WZ, Ferng TL. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerg Infect Dis. 2004;10(2):305–10. doi:https://doi.org/10.3201/eid1002.030731.
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–96. doi:https://doi.org/10.1073/pnas.2004168117.
- Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis. 2020. doi:https://doi.org/10.1093/infdis/jiaa228.
- Tamburello A, Marando M. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives. Swiss Med Wkly. 2020;150:w20264. doi:https://doi.org/10.4414/smw.2020.20264.
- Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. doi:https://doi.org/10.1002/jmv.25882.
- Khamis F, Al-Zakwani I, Al-Hashmi S, Al-Dowaiki S, Al-Bahrani M, Pandak N, Al-Khalili H, Memish Z. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection. Int J Infect Dis. 2020. doi:https://doi.org/10.1016/j.ijid.2020.06.064.
- Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic Proc. 2020. doi:https://doi.org/10.1016/j.mayocp.2020.06.028.
- Erkurt MA, Sarici A, Berber I, Kuku I, Kaya E, Ozgul M. Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia. Transfus Apher Sci. 2020. doi:https://doi.org/10.1016/j.transci.2020.102867.
- Abdullah HM, Hama-Ali HH, Ahmed SN, Ali KM, Karadakhy KA, Mahmood SO, Mahmood ZH, Amin KQH, Atta PM, Nuradeen BE, et al. Severe refractory COVID-19 patients responding to convalescent plasma; A case series. Ann Med Surg. 2020;56:125–27. doi:https://doi.org/10.1016/j.amsu.2020.06.018.
- Abolghasemi H, Eshghi P, Cheraghali AM, Fooladi AAI, Moghaddam FB, Imanizadeh S, Maleki MM, Ranjkesh M, Rezapour M, Bahramifar A, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transf Apher Sci. 2020;102875. doi:https://doi.org/10.1016/j.transci.2020.102875.
- Yadav T, Saxena SK. Transmission cycle of SARS-CoV and SARS-CoV-2. Coronavirus Disease 2019 (COVID-19). 2020;33–42. doi:https://doi.org/10.1007/978-981-15-4814-7_4.
- Sharma R, Agarwal M, Gupta M, Somendra S, Saxena SK. Clinical characteristics and differential clinical diagnosis of novel coronavirus disease 2019 (COVID-19). Coronavirus Disease 2019 (COVID-19). 2020:55–70. doi: https://doi.org/10.1007/978-981-15-4814-7_6.
- Padhi A, Kumar S, Gupta E, Saxena SK. Laboratory diagnosis of novel coronavirus disease 2019 (COVID-19) infection. Coronavirus Disease 2019 (COVID-19) 2020;95–107. doi:https://doi.org/10.1007/978-981-15-4814-7_9.
- Baxi P, Saxena SK. Emergence and reemergence of severe acute respiratory syndrome (SARS) coronaviruses. Coronavirus Disease 2019 (COVID-19) 2020:151–163. doi:https://doi.org/10.1007/978-981-15-4814-7_13.
- Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus Disease 2019 (COVID-19) 2020:23–31. doi:https://doi.org/10.1007/978-981-15-4814-7_3.
- Kumar S, Nyodu R, Maurya VK, Saxena SK. Host immune response and immunobiology of human SARS-CoV-2 infection. Coronavirus Disease 2019 (COVID-19) 2020:43–53. doi:https://doi.org/10.1007/978-981-15-4814-7_5.
- Maurya VK, Kumar S, Bhatt MLB, Saxena SK. Therapeutic development and drugs for the treatment of COVID-19. Coronavirus Disease 2019 (COVID-19) 2020:109–126. doi:https://doi.org/10.1007/978-981-15-4814-7_10.
- Srivastava N, Saxena SK. Prevention and control strategies for SARS-CoV-2 infection. Coronavirus Disease 2019 (COVID-19) 2020:127–140. doi:https://doi.org/10.1007/978-981-15-4814-7_11.
- Chawla S, Saxena SK. Preparing for the perpetual challenges of pandemics of coronavirus infections with special focus on SARS-CoV-2. Coronavirus Disease 2019 (COVID-19) 2020:165–186. doi:https://doi.org/10.1007/978-981-15-4814-7_14.
- Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020:2000858. doi:https://doi.org/10.1183/13993003.00858-2020.
- Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, Naiker M. Natural product-derived phytochemicals as potential agents against coronaviruses: a review. Virus Res. 2020:197989. doi:https://doi.org/10.1016/j.virusres.2020.197989.
- Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671–680.e2. doi:https://doi.org/10.1016/j.chom.2020.03.002.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Sci. 2020;367(6483):1260–63. doi:https://doi.org/10.1126/science.abb2507.
- Ota M. Will we see protection or reinfection in COVID-19? Nat Rev Immunol. 2020. doi:https://doi.org/10.1038/s41577-020-0316-3.